Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

erest related to the settlement reached with U.S. Attorney's Office.

(8) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(9) To exclude charges related to the acquisition of licensed technology in the oncology field.

(10) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED SALES DETAIL

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2008

United

States Europe Total

Sales:

PROVIGIL $241,366 $17,793 259,159

GABITRIL 12,176 2,337 14,513

CNS 253,542 20,130 273,672

ACTIQ 21,392 14,401 35,793

Generic OTFC 19,569 - 19,569

FENTORA 41,330 - 41,330

AMRIX 20,512 - 20,512

Pain
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... CentrePoint Study Admin system was developed to solve many of the ... analysis, particularly within studies that involve multiple clinical sites and/or remote data coordination ...
(Date:7/6/2015)... Calif. , July 6, 2015  Approximately 1% ... is integrated into their chromosomes. These individuals are three ... new study published in one of the nation,s leading ... of Medicine in Canada.  Photo - ... human herpesvirus 6 (HHV-6) causes roseola (also known as ...
(Date:7/6/2015)... 6, 2015 Navitas, a leading Regulatory Service provider, today announced ... hub in Bogota, Colombia . Navitas, expansion into ... provided by Colombia , the third largest economy in ... Logo - http://photos.prnewswire.com/prnh/20150703/228239LOGO ... based clients to communicate with Navitas regulatory professionals in close to or ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... by Fortune 500 companies and professional service industries alike-- typically known for its ... clients laugh, honor a good cause and break from their day jobs. , ...
Breaking Biology Technology:ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 2Navitas Launches Latin American Regulatory Operations Hub in Bogota, Colombia 3The Alexander Group Declares Their Independence with a Bit of Levity 2
... GENEVA , February 3 Viroblock SA, ... products, today,announced that Dr. Jamie Paterson will join Viroblock ... Paterson , a British national, can look back at 20 years ... Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter & ...
... This release is available in German . ... A white light appears out of nowhere. And a light ... upon close examination does the source of the apparently supernatural ... passes through thousands of infinitesimal lens structures measuring only a ...
... ... drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. ... Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about ... ...
Cached Biology Technology:Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2Nano for the senses 2Nano for the senses 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 2Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 4
(Date:6/17/2015)... HILDEN, Germany , June 17, 2015 /PRNewswire/ ... Prime Standard: QIA) today launched new Investigator ® STR ... in the United States . The new ... multiple key genomic markers (short tandem repeats or STRs) for ... to evaluate the quality of DNA in each sample, a ...
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Jewish Health and four other research centers have been ... Heart Lung and Blood Institute as part of the ... national scientists to delve deeply into the biology of ... therapeutic options. The multi-center Lung Genomics Research Consortium will ...
... CITY, Calif., Oct. 7 DigitalPersona, Inc., a ... announced that Panasonic System Solutions Company is now ... field-upgradeable option on Panasonic,s modular point-of-sale (POS) workstation, ... a modular case that can be attached to ...
... degradation in dryland regions continuing to worsen, the ... scientist-recommended indicators for monitoring and assessing desertification that ... agreement was reached after two weeks of negotiations ... the Ninth Session of the Conference of the ...
Cached Biology News:NHLBI awards $11 million for molecular roadmap to chronic lung diseases 2Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
Request Info...
... new Thermo Electron RapidStak provides valuable walk-away ... a unique buffer nest technology for parallel ... RapidStak provides fast, reliable automation for any ... walk-away confidence. The RapidStak can be set-up ...
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
Biology Products: